Transfection in vivo

Adeno Associated Virus (AAV) Packaging System![]() Adenovirus Vector System Plasmids |
Promise-ORFTM viral CDNA library![]() Lentivirus Vector System |
Transfection in vitro can be mediated by the non-viral reagents (such as liposome, polymer, nano-particle) or viral vectors (such as lentiviruses, adenovirus and AAV).
Non-viral methods
Formulations of liposome, polymer and nano-particle have been optimized for in vivo delivery, especially with the use of transfection enhancer and secondary injection. What’s more, the three non-viral methods can also be combined together (Figure 1). As shown in Figure 1, multifunctional envelope-type nano-devices (MEND) are designed to promote the delivery of DNA and RNA. In MEND, PEG is used to extend nucleic acids’ half-life in systemic circulation, ligands are for specific targeting, peptides, including a protein-transduction domain, are intend to increase intracellular availability, while membrane fusogenic lipids were utilized to enhance endosomal escape and protect the degradation of nucleic acids [10,15]. Figure 1. Schematic representation of multifunctional envelope-type nano-devices (MEND), which covers the advantages of liposome, polymer and nano-particle mediated transfection. [10]

Viral vector
Lentiviruses can integrate a significant amount of viral cDNA into the host genome, mediate stable and long-term transgene expression, and efficiently infect dividing cells and nondividing cells in vivo [19]. You could find a lot of information and protocol about lentivirus on this website: https://www.genemedi.net/i/lentivirus-packaging.With no integration ability, recombinant adenovirus can’t be integrated into host genome, have large cargo capacity (~8kb), and are easily manipulated with recombinant DNA techniques [20]. Genemedi got a rich experience in adenovirus packaging and purification, you could find more information on https://www.genemedi.net/i/aav-packaging.
With mild immunogenicity, adeno-associated viruses (AAV) have superior biosafety rating and broad range of infectivity and mediate long-term and stable expression of target gene in vivo [21]. Genemedi is good at lentivirus production, please find more information on this website: https://www.genemedi.net/i/aav-packaging.
Comparison | Retrovirus | Lentivirus | Adenovirus | AAV |
Genome | ss RNA | ss RNA | ds DNA | ss DNA |
Integration | Yes | Yes | No | No |
Packaging Capacity | 3kb | 4kb | 5.5kb | 2kb |
Time to peak expression | 72h | 72h | 36h-72h | Cell: 7 days; Animals: 2 weeks |
Sustainable time | About 3 weeks | Stable expression | Transient expression | > 6 months |
Cell Type | Most Dividing | Most Dividing/Non-Dividing Cells | Most Dividing/Non-Dividing Cells | Most Dividing/Non-Dividing Cells |
Titer | 10^7 TU/ml | 10^8 TU/ml | 10^11 PFU/ml | 10^12 vg/ml |
Animal experiment | Suitable | Low efficiency | Lowest efficiency | Most suitable |
Immune Response | High | Medium | Medium | Ultra-low |

View Knowledge Base - Landscape of in vitro cell transfection and in vivo transfection>>
Other knowledge bases
AAV Knowledge Base![]() CRISPR/Cas9-gRNA system Knowledge Base |
Adenovirus Knowledge Base![]() Transfection Knowledge Base |
Lentivirus Knowledge Base![]() Advanced cell therapy |